Phio Pharmaceuticals Corp.
PHIO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001533040
In the last 90 days, Phio Pharmaceuticals Corp. insiders filed 5 open-market purchases and 0 sales; 24 institutions reported holding it in 13F filings for Q2 2026, worth $662.6K in total; no superinvestor holds it.
13F holders, Q2 2026
Institutional positions in Phio Pharmaceuticals Corp. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 24
- 0 vs. Q1 2026
- Shares held
- 647.1K
- −21.4K (−3.2%) vs. Q1 2026
- Total value
- $662.6K
- −$152.4K (−18.7%) vs. Q1 2026
- New holders
- 4
- 6 more added
- Sold out
- 4
- 8 more reduced
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PHIO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 24 | $662.6K |
| Q1 2026 | 24 | $815.0K |
| Q4 2025 | 17 | $382.3K |
| Q3 2025 | 11 | $467.4K |
| Q2 2025 | 11 | $387.4K |
| Q1 2025 | 11 | $130.8K |
| Q4 2024 | 11 | $277.4K |
| Q3 2024 | 6 | $98.3K |
| Q2 2024 | 12 | $117.0K |
| Q1 2024 | 10 | $106.1K |
| Q4 2023 | 14 | $388.8K |
| Q3 2023 | 14 | $445.4K |
| Q2 2023 | 13 | $798.3K |
| Q1 2023 | 8 | $219.7K |
| Q4 2022 | 12 | $213.2K |
| Q3 2022 | 15 | $415.0K |
| Q2 2022 | 13 | $551.0K |
| Q1 2022 | 15 | $626.0K |
| Q4 2021 | 18 | $991.0K |
| Q3 2021 | 16 | $1.82M |
| Q2 2021 | 17 | $1.58M |
| Q1 2021 | 16 | $1.34M |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding Phio Pharmaceuticals Corp.; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Caitong International Asset Management Co., Ltd | 6 | $6 | 0.00% | +3+100.0% | Added |
| Activest Wealth Management | 9 | $9 | 0.00% | 00.0% | Unchanged |
| Assetmark, Inc | 110 | $113 | 0.00% | 00.0% | Unchanged |
| Barclays PLC | 231 | $237 | 0.00% | +231 | New |
| SBI Securities Co., Ltd. | 1,247 | $1.28K | 0.00% | +23+1.9% | Added |
| Spire Wealth Management | 1,990 | $2.05K | 0.00% | −10−0.5% | Reduced |
| Advisor Group Holdings, Inc. | 2,000 | $2.06K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 5,387 | $5.52K | 0.00% | −21,600−80.0% | Reduced |
| Morgan Stanley | 6,000 | $6.15K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 6,206 | $6.36K | 0.00% | −1,414−18.6% | Reduced |
| Captrust Financial Advisors | 10,000 | $10.3K | 0.00% | 00.0% | Unchanged |
| Citigroup Inc | 11,605 | $11.9K | 0.00% | +10,580+1,032.2% | Added |
| Bridgeway Capital Management, LLC | 12,000 | $12.3K | 0.00% | +12,000 | New |
| HRT Financial LP | 13,182 | $13.0K | 0.00% | −21,550−62.0% | Reduced |
| XTX Topco Ltd | 18,475 | $18.9K | 0.00% | −6,393−25.7% | Reduced |
| Two Sigma Investments, LP | 21,501 | $22.0K | 0.00% | −10,994−33.8% | Reduced |
| Northern Trust Corp | 27,768 | $28.5K | 0.00% | +4,010+16.9% | Added |
| Vanguard Fiduciary Trust Co | 38,169 | $39.1K | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 47,150 | $48.3K | 0.00% | +47,150 | New |
| Cetera Investment Advisers | 47,500 | $48.7K | 0.00% | +2,500+5.6% | Added |
| Nomura Asset Management International Inc. | 50,000 | $51.0K | 0.00% | +50,000 | New |
| Vanguard Capital Management LLC | 94,262 | $96.6K | 0.00% | +14,409+18.0% | Added |
| Geode Capital Management, LLC | 114,574 | $117.4K | 0.00% | −32,680−22.2% | Reduced |
| Jane Street Group, LLC | 117,755 | $120.7K | 0.00% | −1,434−1.2% | Reduced |
| Scientech Research LLC | 0 | $0 | 0.00% | −30,032−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −19,864−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −15,224−100.0% | Sold out |
| NBC Securities, Inc. | 0 | $0 | 0.00% | −1,074−100.0% | Sold out |